Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback